HMG-CoA Reductase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
{{STRUCTURE_1dq8| right| PDB=1dq8 | SCENE=HMG-CoA_Reductase/1dq8_starting_scene/1 |CAPTION= Crystal Structure of Human HMG-CoA Reductase Catalytic Domain, [[1dq8]] }}
{{STRUCTURE_1dq8| right| PDB=1dq8 | SCENE=HMG-CoA_Reductase/1dq8_starting_scene/1 |CAPTION= Crystal Structure of Human HMG-CoA Reductase Catalytic Domain, [[1dq8]] }}
[[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductasese''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a polytopic, transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman"/> It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world.
[[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductasese''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a polytopic, transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman"/> It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world.
-
[[Image: HMG-CoA_reductase_pathway.png|250px|left|thumb| Mevalonate Pathway. Note the early stage at which the Statins interfere in the pathway]]
+
[[Image: HMG-CoA_reductase_pathway.png|250px|left|thumb| Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway]]
<br />
<br />

Revision as of 15:20, 31 October 2010

Human HMG-CoA Reductase Catalytic Domain, 1dqa
Human HMG-CoA Reductase Catalytic Domain, 1dqa

PDB ID 1dq8

Drag the structure with the mouse to rotate
Crystal Structure of Human HMG-CoA Reductase Catalytic Domain, 1dq8
Ligands: , ,
Activity: Hydroxymethylglutaryl-CoA reductase (NADPH), with EC number 1.1.1.34
Resources: FirstGlance, OCA, RCSB, PDBsum
Coordinates: save as pdb, mmCIF, xml


HMG-CoA Reductase (or 3-hydroxy-3-methyl-glutaryl-CoA reductasese or HMGR) is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a polytopic, transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.[1] It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world.

Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway
Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway



Contents

Biological Role

HMGR is among the most highly regulated enzymes in the human body. It catalyzes the formation of mevalonic acid, the committed step in the biosynthesis of sterols, most notably cholesterol. This reaction can be seen below where HMG-CoA is reduced by NADPH. Despite the poor reputation cholesterol has in the media, it is a critical component of cellular membranes as it is required to establish proper membrane permeability and fluidity. The mevalonate pathway is also responsible for synthesis of the oxygen transporting heme found in red blood cells. [2]

PDB ID 1aoi

Drag the structure with the mouse to rotate

Medical Implications

Comparison of Chemical Structure of HMG-CoA and Lovastatin
Comparison of Chemical Structure of HMG-CoA and Lovastatin

Crystal Structure of Human HMGR

Drag the structure with the mouse to rotate

Elevated cholesterol levels have been identified as a major risk factor for coronary artery disease, the narrowing of arteries of the heart, which affected over 13 million people in the United States alone. It is a major cause of disability and death, killing over 500 thousand people in the USA in 2001. [3]

The statins are HMG-CoA reductase inhibitors. Discovered by Akira Endo in 1971 [4], stains are similar in structure to HMG-CoA and act by competitively inhibiting HMGR. Since HMGR is the first committed enzyme in the cascade that eventually produces cholesterol, use of statins can dramatically reduce blood cholesterol levels. As a drug class, statins generated over $20 billion dollars in sales in 2009 with Pfizer’s lipitor the best selling drug in the world. [5][6]

A number of crystal structures of HMGR with bound statins have been solved which elucidate how the statin molecule is bound by HMGR. Statins in general occupy the active site of HMGR, preventing HMG-CoA from being bound by the enzyme. The structures of HMGR with bound , , , , , and highlight the important residues involved in inhibitor binding. The cis loop forms a number of polar interactions with the inhibitor, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of the statins. [7]These interactions serve to allow the statins to be bound by HMGR with a Ki of between .1-2.3nM while the Michaelis constant for HMG-CoA is 4uM. [8]

Additional 3D Structures of HMG-CoA Reductase

3cct, 3ccw, 3ccz, 3cd0, 3cd5, 3cd7, 3cda, 3cdb – HMG-CoA Reductase Catalytic Domain
2qil – HMG-CoA Reductase Catalytic Domain
2q6b, 2q6c – Catalytic Domain of HMG-CoA Reductase
1t02 – Crystal Structure of Statin Bound HMG-CoA Reductase
1r31 – Crystal Structure of HMGR from Pseudomonas mevalonii
1hw8, 1hw9, 1hwi, 1hwj, 1hwk, 1hwl – HMG CoA Reductase with Various Statins Bound
1qax, 1qay – Ternary Complex of Pseudomonas Mevalonii HMGR with mevalonate

Additional Resources

References

  1. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named Roitelman
  2. ↑ Meigs TE, Roseman DS, Simoni RD. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem. 1996 Apr 5;271(14):7916-22. PMID:8626470
  3. ↑ www.nhlbi.nih.gov/health/.../Diseases/.../CAD_WhatIs.html
  4. ↑ Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976 Dec 31;72(2):323-6. PMID:16386050
  5. ↑ http://www.drugs.com/top200.html
  6. ↑ http://www.medicalnewstoday.com/articles/25046.php
  7. ↑ Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001 May 11;292(5519):1160-4. PMID:11349148 doi:10.1126/science.1059344
  8. ↑ Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9-27. PMID:7784310
Retrieved from "http://52.214.119.220/wiki/index.php/HMG-CoA_Reductase"
Personal tools